MarketCapExport financials
Alexion Pharmaceuticals, Inc. (ALXN)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
TelegramAlexion Pharmaceuticals, Inc. Financial Ratios 2020-2011 | ALXN
Brief overview of Alexion Pharmaceuticals, Inc.'s multiples and efficiency
Current figures are compared with the company's own five-year history for 2016–2020.
Market valuation is represented by P/E 55.68x (median 61.8x), EV/EBITDA 10.66x (median 14.88x), P/S 5.53x (median 6.54x). The combined multiple level is about 15.4% below the company's historical norm, suggesting more cautious expectations.
The 1/P/E calculation produces a 1.8% earnings yield. It does not capture future growth or capital structure.
Current measures of operating quality are ROE 5.2%, ROA 3.3%, ROCE 17.4%. Business quality is below comfortable levels on current returns. Better margins or turnover are needed.
The cash conversion cycle shortened from 105.5 days to 12.8 days, or 92.7 days. Working capital returns faster.
Overall assessment
Alexion Pharmaceuticals, Inc.'s valuation is lower, but weak quality metrics call for caution. Recovery in earnings and capital returns is the key catalyst.
Annual Financial Ratios Alexion Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E |
55.7 | 9.3 | 348.2 | 61.8 | 71.9 | 215.7 | 55.3 | 125.3 | 71.3 | 78.4 |
P/S |
5.5 | 4.5 | 6.5 | 7.7 | 9.3 | 12.0 | 16.3 | 20.4 | 16.0 | 17.5 |
EV/EBITDA |
10.7 | 9.1 | 14.9 | 26.4 | 27.6 | 42.0 | 36.8 | 55.1 | 38.2 | 54.0 |
PEG |
-0.75 | 0.0 | -4.23 | 5.5 | 0.44 | -2.71 | 0.35 | -33.57 | 1.8 | 1.03 |
P/B |
2.9 | 2.0 | 2.9 | 3.1 | 3.3 | 3.8 | 11.0 | 13.3 | 9.2 | 12.1 |
P/CF |
11.6 | 11.7 | 126.8 | 36.1 | 38.1 | 80.1 | 72.1 | 67.7 | 46.7 | 55.4 |
ROE % |
5.18 | 21.33 | 0.85 | 4.98 | 4.59 | 1.75 | 19.89 | 10.62 | 12.93 | 15.45 |
ROA % |
3.33 | 13.70 | 0.56 | 3.26 | 3.01 | 1.10 | 15.63 | 7.62 | 9.75 | 12.57 |
ROCE % |
17.36 | 13.09 | 12.50 | 6.37 | 6.38 | 5.50 | 25.47 | 20.71 | 20.12 | 20.98 |
DSO |
84.7 | 90.9 | 81.5 | 74.7 | 76.9 | 74.7 | 70.7 | 99.2 | 95.1 | 113.8 |
DIO |
511.5 | 580.7 | 460.8 | 370.0 | 530.5 | 453.9 | 370.4 | 210.9 | 473.7 | 318.9 |
DPO |
78.2 | 68.5 | 72.6 | 56.9 | 90.5 | 89.8 | 92.4 | 44.4 | 107.7 | 62.8 |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Alexion Pharmaceuticals, Inc., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
Russia
Schweiz
Britain
